Relmada Therapeutics (RLMD)

Relmada Therapeutics Financial Statements

Relmada Therapeutics Financial Overview

Relmada Therapeutics's market cap is currently ―. The company's EPS TTM is $-7.195; its P/E ratio is -3.64; Relmada Therapeutics is scheduled to report earnings on August 11, 2022, and the estimated EPS forecast is $-1.27. See an overview of income statement, balance sheet, and cash flow financials.
Mar 22Dec 21Sep 21Jun 21Mar 21
Income Statement
Total Revenue$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit$ ―$ ―$ ―$ ―$ ―
EBIT$ -38.30M$ -34.18M$ -42.65M$ -26.46M$ -22.41M
EBITDA$ -38.30M$ -34.18M$ -42.65M$ -26.46M$ -22.40M
Net Income Common Stockholders$ -39.75M$ -34.38M$ -42.61M$ -26.55M$ -22.22M
Balance Sheet
Cash, Cash Equivalents and Short-Term Investments$ 88.09M$ 102.70M$ 109.07M$ 117.09M$ 123.14M
Total Assets$ 225.81M$ 223.33M$ 90.93M$ 110.77M$ 103.87M
Total Debt$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Net Debt$ -88.09M$ -102.70M$ -109.07M$ -117.09M$ -123.14M
Total Liabilities$ 15.41M$ 15.06M$ 18.25M$ 13.92M$ 12.72M
Stockholders Equity$ 72.69M$ 91.15M$ 96.85M$ 105.58M$ 122.21M
Cash Flow
Free Cash Flow$ -19.43M$ -37.66M$ -20.92M$ -17.21M$ -16.09M
Operating Cash Flow$ -19.43M$ -37.66M$ -20.92M$ -17.21M$ -16.09M
Investing Cash Flow$ -10.03M$ -91.18M$ 27.51M$ -5.91M$ 15.47M
Financing Cash Flow$ 29.95M$ 161.84M$ 185.16K$ 23.99M$ 1.93M
Currency in USD

Relmada Therapeutics Earnings and Revenue History

Relmada Therapeutics Debt to Assets

Relmada Therapeutics Cash Flow

Relmada Therapeutics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis